Poly Medicure reports a significant decrease in Q4 profits by 27.8% compared to last year, while revenue shows a positive growth of 21.3%. Despite the profit drop, the company's revenue increase suggests ongoing efforts to boost sales and maintain business resilience.

By FY27, Poly Medicure plans to achieve a significant revenue milestone of INR 2,400 crores, spurred by strategic growth initiatives.

Poly Medicure sets a revenue goal of INR 2,300 crores by the fiscal year 2027, with a focus on reducing receivable days to 90. The company also plans to increase dialysis unit sales from 450 in the current fiscal year to 550 in FY27.

Poly Medicure's EBITDA decreased by approximately 10% in the fourth quarter, reaching ₹1.1B, with a corresponding drop in profit margins from 27% to 20.7%.

Poly Medicure will release their Q4 FY26 results on May 25, 2026. Investors are anticipating upcoming meetings that could impact the company's share value.

Poly Medicure's shares experienced a 5% decrease due to a 27.8% year-on-year drop in Q4 net profit to 66.3 crores, despite a 21.3% revenue growth to 534.5 crores. The company reported an increase in domestic and international revenues for FY26, with a 19.6% rise domestically and 9.3% internationally. EBITDA margin remained steady at 24.4%, and a dividend of ₹3.5 per share was proposed.

Poly Medicure's CEO, Himanshu Baid, discussed the company's Q4 normalized EBITDA margins, addressing unexpected impacts that influenced the results compared to the provided guidance by management.

Poly Medicure Ltd has announced impressive financial results for FY26, including a recommended dividend of Rs. 3.5 per share. The company's auditors have also been reappointed for FY27, indicating confidence in their continued financial strength and performance.

Hitachi Energy, Suzlon Energy, and several other companies like Rail Vikas Nigam, Sundaram Finance, CONCOR, NBCC, Pine Labs, and Poly Medicure are all set to release their Q4 financial results today. Investors will be eagerly awaiting the updates on these firms' performance for the quarter ending in December 2021.

On May 25, 2026, Poly Medicure's board meeting will be held to discuss their audited financial results, including a potential final dividend payout for shareholders. The trading window will remain closed until May 27, 2026, ahead of the announcement.

Poly Medicure's subsidiary Polymed Brazil LIDA has bought MEDYNEO, gaining full ownership. This move secures the rights to medical device licenses in Brazil starting from April 29, 2026, as per the R 180,000 acquisition deal.